SCHEMBL6581336

SCHEMBL6581336

NNC(=O)c1ccc2c(c1)OCCO2

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.67
MAPK1 P28482 1/20 0.67
TSHR P16473 1/20 0.66
SMN1; SMN2 Q16637 4/20 0.63
RAB9A P51151 7/20 0.62
NPC1 O15118 6/20 0.62
MAOB P27338 5/20 0.62
PKM P14618 1/20 0.62
NFKB1 P19838 1/20 0.62
NFKB2 Q00653 1/20 0.62
RELA Q04206 1/20 0.62
HPGD P15428 3/20 0.61
HSD17B10 Q99714 1/20 0.61
ALDH1A1 P00352 1/20 0.60
ATM Q13315 1/20 0.60
TP53 P04637 2/20 0.59
MAPT P10636 1/20 0.59
MEN1 O00255 1/20 0.59
KMT2A Q03164 1/20 0.59
KLF5 Q13887 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18101216 0.95 KDM4E (0.64) KDM4EMAPK1TSHRSMN1; SMN2RAB9A
SCHEMBL18101260 0.95 KDM4E (0.64) KDM4EMAPK1TSHRSMN1; SMN2RAB9A
SCHEMBL18101256 0.95 KDM4E (0.64) KDM4EMAPK1TSHRSMN1; SMN2RAB9A
SCHEMBL18101254 0.95 KDM4E (0.64) KDM4EMAPK1TSHRSMN1; SMN2RAB9A
SCHEMBL31019604 0.89 NPC1 (0.66) MAPK1SMN1; SMN2RAB9ANPC1PKM
SCHEMBL133893 0.89 NPC1 (0.66) MAPK1SMN1; SMN2RAB9ANPC1PKM
SCHEMBL13605449 0.82 NPC1 (0.67) KDM4EMAPK1TSHRSMN1; SMN2RAB9A
SCHEMBL1395940 0.81 TAS1R3 (0.63) KDM4EMAPK1TSHRSMN1; SMN2RAB9A
SCHEMBL13702386 0.81 KDM4E (0.70) KDM4EMAPK1TSHRSMN1; SMN2RAB9A
SCHEMBL17604678 0.80 KDM4E (0.46) KDM4EMAPK1TSHRSMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346588-A1 IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS KUDA THERAPEUTICS INC (US) 2025-11-13 US disclosed
CN-116730995-B Hydrazide compound, preparation method and application thereof 深圳微芯生物科技股份有限公司 2024-06-25 CN disclosed
US-11634391-B2 Compounds which are inhibitors of Notum UCL BUSINESS LTD (GB) 2023-04-25 US disclosed
US-20210171475-A1 COMPOUNDS UCL BUSINESS LTD (GB) 2021-06-10 US disclosed
EP-1070708-B1 Triazole derivatives HOFFMANN LA ROCHE (CH) 2004-01-14 EP disclosed
US-6265426-B1 CENTRAL NERVOUS SYSTEM DISORDERS HOFFMANN-LA ROCHE INC. 2001-07-24 US disclosed
EP-1070708-A1 Triazole and imidazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 2001-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11634391-B2 Compounds which are inhibitors of Notum NOTUM, GOT2, GOT1 KDM4E 3907/4885MAPK1 1270/4885TSHR 4585/4885
US-20250346588-A1 IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS HIF1AN, HIF1A, EGLN2 KDM4E 1020/4885MAPK1 815/4885TSHR 1368/4885
US-20210171475-A1 COMPOUNDS GOT2, GOT1, OAT KDM4E 4149/4885MAPK1 2807/4885TSHR 4463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.